Cell and Gene Therapy for Personalised Medicine (CGT4PM2027)

Identifier: HORIZON-HLTH-2023-CARE-08-01 Status: Open Submission procedure: single-stage Opening date: 2026-11-04 Deadline: 2027-01-20 Budget: €37,000,000 With this JTC, EP PerMed will fund research projects in human health on Cell and Gene Therapies (CGT) for PM approaches. Proposals must focus on the development and validation of an innovative and novel CGT for PM. At least one of the following approaches must be employed: • Somatic cell therapeutics; • Gene therapeutics; • Combined cell- and gene therapeutics; • Novel biological products. For the entire scope, please consult the Call Text: https://www.eppermed.eu/funding-projects/calls/jtc2027/. Applicants should contact their corresponding regional/national representative to enquire about eligibility with their respective funding organisations prior to submitting an application (see regional/national contact details, Annex I of the call text). For additional information, please contact the JCS (EPPerMed@anr.fr). Adherence to the regional/national funding regulations in the “Guidelines for Applicants” document is mandatory (www.eppermed.eu).